Recent Advances in the Synthesis of Antidepressant Derivatives: Pharmacologic Insights for Mood Disorders

Overview

Journal 3 Biotech

Publisher Springer

Specialty Biotechnology

Date 2024 Oct 8

PMID 39376479

Authors

Jeetendra Kumar Gupta

Kuldeep Singh

Alok Bhatt

Prateek Porwal

Rekha Rani

Anubhav Dubey

Divya Jain

Sachchida Nand Rai

Affiliations

Soon will be listed here.

Abstract

Mood disorders, including depression, remain a significant global health concern, necessitating continuous efforts to develop novel and more effective antidepressant therapies. Although there have been significant advancements in comprehending the biology of Major Depressive Disorder (MDD), a considerable number of people suffering from depression do not exhibit positive responses to the pharmacologic treatments now available. This study specifically examines emerging targets and potential future approaches for pharmaceutical interventions in the treatment of MDD. The discussion revolves around novel therapeutic agents and their effectiveness in treating depression. The focus is on the specific pathophysiological pathways targeted by these agents and the amount of evidence supporting their use. While conventional antidepressants are anticipated to continue being the primary treatment for MDD in the foreseeable future, there is currently extensive research being conducted on numerous new compounds to determine their effectiveness in treating MDD. Many of these compounds have shown encouraging results. This review highlighted the recent advances in the synthesis of antidepressant derivatives and explores their pharmacologic insights for the treatment of mood disorders.

Citing Articles

Advances in Antidepressant Therapy: Comparing the Efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Novel Agents.

Nawaz A, Mamoon B, Batool T, Khattak M, Amir F, Akbar A Cureus. 2025; 16(12):e76318.

PMID: 39850187 PMC: 11756613. DOI: 10.7759/cureus.76318.

References

Mattson R, Catt J, Denhart D, Deskus J, Ditta J, Higgins M . Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J Med Chem. 2005; 48(19):6023-34. DOI: 10.1021/jm0503291. View

Aboukhatwa M, Undieh A . Antidepressant stimulation of CDP-diacylglycerol synthesis does not require monoamine reuptake inhibition. BMC Neurosci. 2010; 11:10. PMC: 2823756. DOI: 10.1186/1471-2202-11-10. View

Zalewska A, Galczyk M, Van Damme-Ostapowicz K . Level of Depression during the COVID-19 Pandemic in Poland-A Cross-Sectional Study. Healthcare (Basel). 2022; 10(6). PMC: 9222724. DOI: 10.3390/healthcare10061123. View

Rehuman N, Mathew B, Jat R, Nicolotti O, Kim H . A Comprehensive Review of Monoamine Oxidase-A Inhibitors in their Syntheses and Potencies. Comb Chem High Throughput Screen. 2020; 23(9):898-914. DOI: 10.2174/1386207323666200428091306. View

Saglik B, Kaya Cavusoglu B, Acar Cevik U, Osmaniye D, Levent S, Ozkay Y . Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling. RSC Med Chem. 2021; 11(9):1063-1074. PMC: 7513386. DOI: 10.1039/d0md00150c. View

Fournier N, Duman R . Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res. 2011; 227(2):440-9. PMC: 3176958. DOI: 10.1016/j.bbr.2011.04.022. View

Chen J, Zhao L, Liu Y, Fan S, Xie P . Comparative efficacy and acceptability of electroconvulsive therapy versus repetitive transcranial magnetic stimulation for major depression: A systematic review and multiple-treatments meta-analysis. Behav Brain Res. 2016; 320:30-36. DOI: 10.1016/j.bbr.2016.11.028. View

Jatav V, Mishra P, Kashaw S, Stables J . CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones. Eur J Med Chem. 2008; 43(9):1945-54. DOI: 10.1016/j.ejmech.2007.12.003. View

Leblhuber F, Geisler S, Ehrlich D, Steiner K, Reibnegger G, Fuchs D . Repetitive transcranial magnetic stimulation in the treatment of resistant depression: changes of specific neurotransmitter precursor amino acids. J Neural Transm (Vienna). 2021; 128(8):1225-1231. PMC: 8321996. DOI: 10.1007/s00702-021-02363-7. View

10.

Ben-Daniel R, Deuther-Conrad W, Scheunemann M, Steinbach J, Brust P, Mishani E . Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter. Bioorg Med Chem. 2008; 16(12):6364-70. DOI: 10.1016/j.bmc.2008.05.006. View

11.

Griebel G, Beeske S, Stahl S . The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2012; 73(11):1403-11. DOI: 10.4088/JCP.12m07804. View

12.

Arias-de la Torre J, Vilagut G, Ronaldson A, Serrano-Blanco A, Martin V, Peters M . Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. Lancet Public Health. 2021; 6(10):e729-e738. PMC: 8460452. DOI: 10.1016/S2468-2667(21)00047-5. View

13.

Bruno A, Morabito P, Spina E, Muscatello M . The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol. 2015; 14(2):191-9. PMC: 4825949. DOI: 10.2174/1570159x14666151117122458. View

14.

Ritter N, Disse P, Wunsch B, Seebohm G, Strutz-Seebohm N . Pharmacological Potential of 3-Benzazepines in NMDAR-Linked Pathophysiological Processes. Biomedicines. 2023; 11(5). PMC: 10216354. DOI: 10.3390/biomedicines11051367. View

15.

Jairath V, Zou G, Parker C, MacDonald J, Mosli M, Khanna R . Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016; 10(5):607-18. PMC: 4957452. DOI: 10.1093/ecco-jcc/jjw004. View

16.

Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg W . Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2013; 39(1):40-9. PMC: 3868664. DOI: 10.1503/jpn.130040. View

17.

Kaggwa M, Najjuka S, Bongomin F, Mamun M, Griffiths M . Prevalence of depression in Uganda: A systematic review and meta-analysis. PLoS One. 2022; 17(10):e0276552. PMC: 9584512. DOI: 10.1371/journal.pone.0276552. View

18.

Serban G, Stanasel O, Serban E, Bota S . 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Des Devel Ther. 2018; 12:1545-1566. PMC: 5987787. DOI: 10.2147/DDDT.S155958. View

19.

Zarate Jr C, Machado-Vieira R . Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders. Mol Psychiatry. 2017; 22(3):324-327. PMC: 5641407. DOI: 10.1038/mp.2016.249. View

20.

Huang X, Yang J, Yang S, Cao S, Qin D, Zhou Y . Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms. Oncotarget. 2017; 8(60):102705-102720. PMC: 5731992. DOI: 10.18632/oncotarget.22170. View